Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that topical minoxidil 5% was more effective than cetirizine 1% in improving hair parameters in male androgenetic alopecia, though cetirizine showed promising safety and some efficacy.

This study observed that after 12 weeks of using the nutraceutical Alpenta, women with acute or chronic telogen effluvium experienced significant improvements in hair growth parameters, including increased anagen hair percentage, hair density, and diameter, with high patient satisfaction and good product tolerability reported.

MpowerTM may improve hair growth and satisfaction more than plain minoxidil, with mild side effects.

In this retrospective study, a combined therapy of ablative fractional Er: YAG laser and medication was more effective in treating male androgenetic alopecia than medication alone, without causing serious adverse effects, as evaluated over 24 weeks.

This study reported that the 1565 nm non-ablative fractional laser treatment significantly improved various hair growth indices in patients with androgenetic alopecia compared to 5% minoxidil, demonstrating its superior clinical efficacy and safety for treating this condition.

This study found that combining low-level light therapy with platelet-rich plasma significantly improved hair parameters in men with androgenic alopecia, although most improvements decreased after treatment stopped.

In this study, intradermal injections of QR678 were found to significantly reduce hair fall in men with androgenetic alopecia over 6 months, with superior improvements in hair density and thickness compared to PRP.

Minoxidil solution and foam both increase hair growth, but the solution works better than the foam.

This study found that trichoscopic parameters in male androgenetic alopecia deteriorated progressively with increasing disease severity and were significantly linked to genetic, metabolic, and psychosocial factors.

This study evaluated salmon-derived exosomes combined with microneedling as a treatment for androgenetic alopecia, reporting significant improvements in hair density, follicular health, and scalp microenvironment, with no serious adverse events observed in the 20 patients after 12 weeks.

This study examined 15 female patients with hypothyroidism to investigate the characterization of their alopecia and ruled out other causes, using medical histories, and clinical, trichoscopic, and histologic findings.

This upcoming clinical trial at Shenzhen People's Hospital will explore the safety and efficacy of human umbilical cord mesenchymal stem cell-derived small extracellular vesicles as a treatment for androgenetic alopecia in young men, comparing them to minoxidil. Results are not reported yet.

In this study, the application of topical cetirizine 1% once daily for four months in Egyptian male patients with androgenetic alopecia led to a significant increase in terminal hairs and improved hair diversity, with promising safety and efficacy outcomes.

Male hair loss is mainly due to thinner hair, not less hair.

This review discusses methods to better identify unsafe donor areas in patients with diffuse unpatterned alopecia, emphasizing non-surgical management when specific diagnostic criteria are met, but reports no new clinical results.

The occipital scalp is affected in advanced hair loss, so it shouldn't be used as a control.

In this study, the researchers found that the topical generic 5% new minoxidil foam is as effective and safe as the 5% Rogaine® foam in increasing hair density and diameter in men with androgenetic alopecia over 24 weeks.

This study found that salmon tissue-derived exosomes showed significantly greater improvements in hair density and other parameters compared to platelet-rich plasma in patients with mild to moderate androgenetic alopecia.

This study found that platelet-rich plasma therapy may effectively improve hair density and related parameters in men with androgenetic alopecia, with results differing based on specific platelet counts.

This letter to the editor discusses the use of topical cetirizine 1% for treating androgenetic alopecia but reports no new clinical outcomes.

This study found that hair canal and follicle diameters, outer root sheath area, and terminal-to-vellus hair ratios were significantly reduced in androgenetic alopecia patients compared to normal controls.

This study reviewed clinical trials and found that low-level laser therapy significantly increased hair diameter or density in both men and women with pattern hair loss compared to a sham device, though the involvement of industry relationships in some studies suggests cautious interpretation.

The study found that combining a 655nm low-level laser helmet with 2% minoxidil resulted in better improvement in hair diameter and intermediate hair enlargement at the midscalp among Chinese women with FPHL.

In this study, researchers found that using a handheld digital microscope, hair diameter was a better determinant of perceived alopecia severity in androgenetic alopecia than hair density.

Topical minoxidil is a safe and effective treatment for hair loss caused by androgenetic alopecia.

This study reported significant improvements in hair density, diameter, and patient satisfaction after using non-enzymatic stromal vascular fraction treatment for androgenic alopecia over six months.

This study found that the cross-section trichometer (HairCheck device) can accurately and sensitively measure hair mass index changes, offering a convenient tool for assessing hair density and diameter in patients with alopecia.

This study found that white females with female pattern hair loss had higher hair density in the occipital scalp area, while Asian females had thicker hair diameters in both frontal and occipital areas.

This study found that hair mesotherapy containing biomimetic peptides, vitamins, and micronutrients significantly improved hair parameters in patients with androgenetic alopecia and was well-tolerated over an 8-session treatment period.

Bicalutamide may improve hair growth in postmenopausal women with mild side effects.